United States

People: Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

1:47pm EDT
Change (% chg)

$-0.59 (-4.45%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Hoberman, Kenneth 

Mr. Kenneth Hoberman serves as Chief Operating Officer of the Company., effective March 25, 2013. Mr. Hoberman has extensive financial, accounting, investor relations, corporate governance and business development experience including M&A, strategic alliances and partnerships both domestic and international. His operational expertise includes regulatory oversight, human resources, manufacturing and clinical development. He was previously Vice President of Corporate and Business Development of Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), where he was instrumental in the success of the company. He also helped secure multiple sources of capital including over $200 million in equity investments through public and private offerings. He also initiated and executed a $100 million strategic alliance and originated, negotiated and closed dozens of licensing and operational contracts, helping to grow the company’s market capitalization to over $1 billion. He also led the team that originated, in-licensed, and developed Auryxia™ which was approved by the FDA in September 2014. He is on the Board of Directors of TG Therapeutics, Inc. (Nasdaq: TGTX). He received a B.S.B.A. in Finance from Boston University and completed post-baccalaureate studies at Columbia University.

Basic Compensation

Total Annual Compensation, USD 687,405
Restricted Stock Awards, USD 1,156,930
Long-Term Incentive Plans, USD --
All Other, USD 28,070
Fiscal Year Total, USD 1,872,400

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 112,940 2,214,990.00
Name Fiscal Year Total

Ivan Bergstein


Kenneth Hoberman


David Gionco


Ron Bentsur


Eric Dobmeier


Alan Forman

As Of  30 Dec 2017